Compare Jones Lang LaSalle Inc (JLL) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jones Lang LaSalle Inc vs Mesoblast Limited — how do they compare? Jones Lang LaSalle Inc trades at $325.29 (market cap $15.12B), while Mesoblast Limited trades at $16.38 (market cap $2.17B). The key difference: Jones Lang LaSalle Inc is far larger — about 7× Mesoblast Limited's market cap, and Jones Lang LaSalle Inc is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| JLL | MESO | |
|---|---|---|
Market Cap | $15.12B | $2.17B |
Sector | Real Estate | Technology |
52-Week High | $358.66 | $20.96 |
52-Week Low | $253.48 | $12.88 |
Enterprise Value | $18.66B | $2.17B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
